• Home
  • Politics
  • Health
  • World
  • Business
  • Finance
  • Tech
  • More
    • Sports
    • Entertainment
    • Lifestyle
What's Hot

Microsoft Bans Employees From Using ‘Chinese Propaganda’ Chatbot

May 9, 2025

How Smart Mattresses Improve Sleep Quality For Couples

May 9, 2025

OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

May 9, 2025
Facebook Twitter Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
Friday, May 9
Patriot Now NewsPatriot Now News
  • Home
  • Politics

    Security video shows brazen sexual assault of California woman by homeless man

    October 24, 2023

    Woman makes disturbing discovery after her boyfriend chases away home intruder who stabbed him

    October 24, 2023

    Poll finds Americans overwhelmingly support Israel’s war on Hamas, but younger Americans defend Hamas

    October 24, 2023

    Off-duty pilot charged with 83 counts of attempted murder after allegedly trying to shut off engines midflight on Alaska Airlines

    October 23, 2023

    Leaked audio of Shelia Jackson Lee abusively cursing staffer

    October 22, 2023
  • Health

    Disparities In Cataract Care Are A Sorry Sight

    October 16, 2023

    Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

    October 16, 2023

    Long-term steroid use should be a last resort

    October 16, 2023

    Rite Aid Files For Bankruptcy With More ‘Underperforming Stores’ To Close

    October 16, 2023

    Who’s Still Dying From Complications Related To Covid-19?

    October 16, 2023
  • World

    New York Democrat Dan Goldman Accuses ‘Conservatives in the South’ of Holding Rallies with ‘Swastikas’

    October 13, 2023

    IDF Ret. Major General Describes Rushing to Save Son, Granddaughter During Hamas Invasion

    October 13, 2023

    Black Lives Matter Group Deletes Tweet Showing Support for Hamas 

    October 13, 2023

    AOC Denounces NYC Rally Cheering Hamas Terrorism: ‘Unacceptable’

    October 13, 2023

    L.A. Prosecutors Call Out Soros-Backed Gascón for Silence on Israel

    October 13, 2023
  • Business

    Microsoft Bans Employees From Using ‘Chinese Propaganda’ Chatbot

    May 9, 2025

    OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

    May 9, 2025

    Trump Announces First Post-Tariff Trade Deal

    May 8, 2025

    Electric Vehicle Sales Nosedive As GOP Takes Buzzsaw To Biden’s Mandate

    May 7, 2025

    Tyson Foods Announces It Will Bend The Knee To Trump Admin’s New Rules

    May 7, 2025
  • Finance

    Ending China’s De Minimis Exception Brings 3 Benefits for Americans

    April 17, 2025

    The Trump Tariff Shock Should Push Indonesia to Reform Its Economy

    April 17, 2025

    Tariff Talks an Opportunity to Reinvigorate the Japan-US Alliance

    April 17, 2025

    How China’s Companies Are Responding to the US Trade War

    April 16, 2025

    The US Flip-flop Over H20 Chip Restrictions 

    April 16, 2025
  • Tech

    Cruz Confronts Zuckerberg on Pointless Warning for Child Porn Searches

    February 2, 2024

    FTX Abandons Plans to Relaunch Crypto Exchange, Commits to Full Repayment of Customers and Creditors

    February 2, 2024

    Elon Musk Proposes Tesla Reincorporates in Texas After Delaware Judge Voids Pay Package

    February 2, 2024

    Tesla’s Elon Musk Tops Disney’s Bob Iger as Most Overrated Chief Executive

    February 2, 2024

    Mark Zuckerberg’s Wealth Grew $84 Billion in 2023 as Pedophiles Target Children on Facebook, Instagram

    February 2, 2024
  • More
    • Sports
    • Entertainment
    • Lifestyle
Patriot Now NewsPatriot Now News
Home»Health»Biotech news, Novavax Covid shot, and more
Health

Biotech news, Novavax Covid shot, and more

October 4, 2023No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech news, Novavax Covid shot, and more
Share
Facebook Twitter LinkedIn Pinterest Email

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, everyone. Damian here with the precarious case of gene therapy in Europe, a long-awaited coup for Novavax, and the unwinding of Amgen’s success story.

The need-to-know this morning
• Sanofi will spend up to $1.5 billion to co-develop and co-commercialize Teva’s experimental arthritis drug as a treatment for inflammatory bowel disease.
• Eli Lilly announced a reshuffling of its leadership, including promoting David Hyman to chief medical officer.

Does gene therapy have a future in Europe?
For Stella Pelteki, who has lived with a blood disorder since birth, the 2019 European approval of a gene therapy for her disease had life-changing potential. But within months, that promise came unglued as the manufacturer failed to persuade continental governments to pay the treatment’s $1.8 million million price tag, leaving Pelteki and thousands of others without access to a long-awaited therapy.

As STAT’s Andrew Joseph reports, the ordeal demonstrated what can happen when a company touting a pricey, powerful treatment collides with cost-conscious national health systems empowered to negotiate prices and skeptical of some of the therapy’s benefits. And in Europe, some fear it could happen again.

As potentially curative, undoubtedly expensive one-time therapies make their way toward the market, advocates are urging companies and payers to find solutions that don’t leave patients like Pelteki unable to get their hands on medicines that could dramatically improve their lives.

Read more.

At last, Novavax is back in the game
Three weeks after its mRNA rivals hit the market, Novavax won FDA clearance for its updated Covid-19 vaccine, giving the company a chance to save its business in the market for boosters.

See also  Donald Trump Attacks Fox News for 'Desperately Pushing' Ron DeSantis as GOP Threat

As STAT’s Helen Branswell reports, yesterday’s news was doubly positive for Novavax. Previously, the FDA had authorized its product only for people who specifically declined an mRNA vaccine. The updated ruling makes Novavax’s vaccine available to anyone who wants.

The challenge now is to find enough of those people to keep the business afloat. Novavax has previously warned shareholders that its dire financial situation poses an existential threat, and the company’s long-term survival hinges on successfully launching its booster into a crowded market with waning demand.

Read more.

Amgen’s pathbreaking drug is on the ropes
Amgen made history in 2021 with the FDA approval of Lumakras, the first cancer drug to successfully target a common but wily genetic mutation. But the company’s confirmatory study has some serious flaws, according to the FDA, putting its future in jeopardy.

As STAT’s Allison DeAngelis reports, agency reviewers cited potential problems with bias in Amgen’s trial. In documents posted ahead of an expert panel meeting later this week, the FDA questioned the company’s conclusions on Lumakras’ efficacy and noted that a high drop-out rate in the comparator group could make the whole study uninterpretable.

Analysts said the likeliest scenario is that the agency’s panel of advisers vote to wait on data from another Phase 3 trial before granting Amgen’s drug full approval. But there’s an outside chance the FDA will seek to remove Lumakras from the market, undoing what had been a story of scientific triumph.

Read more.

Lilly is breaking with pharma tradition
There’s a time-honored tradition among major drugmakers in which great windfalls — whether from Lipitor, Humira, or a Covid-19 vaccine — are followed by periods of wasteful spending on bad acquisitions at shocking prices. Eli Lilly, as Evercore ISI analysts Umer Raffat and Jon Miller noted yesterday, has been doing the opposite.

See also  New weight loss drugs vying to be the next Wegovy or Mounjaro

The latest example is its $1.4 billion deal for Point Biopharma, a company working in the fast-growing field of cancer drugs that deliver a focused dose of radiation to tumor cells. As STAT’s Matthew Herper points out, the deal gives Lilly a foothold in so-called radiopharmaceuticals, which have been a bright spot in the business of rival Novartis.

It’s the latest in a string of what Raffat and Miller called a careful approach to pharmaceutical business development. In June it bought Dice Therapeutics, which is developing a pill to treat autoimmune disease, for $2.4 billion. And in July, Lilly purchased Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, for less than $2 billion. Neither deal shook up the industry, but each provided a reasonably priced complement to something Lilly already does well.

Read more.

More reads
• Novartis weighs selling assets from radiopharma unit, Bloomberg
• Boehringer launches 81% discounted biosimilar of AbbVie’s Humira, Reuters

Biotech Covid News Novavax shot
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

China’s Export Economy Under Trump’s Tariff Onslaught The Worst Since COVID

April 30, 2025

‘Golden Age Has Begun’: March Jobs Report Spells Great News For Trump

April 4, 2025

‘Midnight Rulemaking’ From Liz Warren’s Favorite Agency Spells Even More Bad News For Cash-Strapped Americans

January 11, 2025

China’s Third Plenum Wants to Raise Household Income. That’s Good News for the US.

July 30, 2024
Add A Comment

Leave A Reply Cancel Reply

Top Posts

Desperate Disney Prepares to Sell Off Third of Company

July 19, 2023

68-year-old woman was sexually assaulted after being dragged to a parking garage, and NYPD says bystanders did nothing

May 3, 2023

Ronan Farrow Documents Elon Musk’s ‘Shadow Rule’ over the War in Ukraine

August 23, 2023

Ukrainian Soldiers Accused of Storming Russian Border and Opening Fire

May 22, 2023
Don't Miss

Microsoft Bans Employees From Using ‘Chinese Propaganda’ Chatbot

Business May 9, 2025

Microsoft has banned employees from using DeepSeek — the viral Chinese chatbot it worries is…

How Smart Mattresses Improve Sleep Quality For Couples

May 9, 2025

OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

May 9, 2025

Short and Funny Sayings for a Happy Summer with Friends

May 9, 2025
About
About

This is your World, Tech, Health, Entertainment and Sports website. We provide the latest breaking news straight from the News industry.

We're social. Connect with us:

Facebook Twitter Instagram Pinterest
Categories
  • Business (4,112)
  • Entertainment (4,220)
  • Finance (3,202)
  • Health (1,938)
  • Lifestyle (1,628)
  • Politics (3,084)
  • Sports (4,036)
  • Tech (2,006)
  • Uncategorized (4)
  • World (3,944)
Our Picks

Exclusive: EV charging firms oppose Texas’ ‘premature’ plan to mandate Tesla standard

July 2, 2023

Cartel Gunmen Hang Bodies from Border State Overpass in Mexico

August 29, 2023

“He is the worst thing for baseball” “Not loudly enough”

July 10, 2023
Popular Posts

Microsoft Bans Employees From Using ‘Chinese Propaganda’ Chatbot

May 9, 2025

How Smart Mattresses Improve Sleep Quality For Couples

May 9, 2025

OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

May 9, 2025
© 2025 Patriotnownews.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.